Inokuchi K
Gan To Kagaku Ryoho. 1983 Feb;10(2 Pt 2):320-5.
The combination of surgery with chemotherapy is mandatory to get a higher survival rate in gastric cancer. A study on adjuvant chemotherapy must be conducted in a setting of controlled trial and include a sufficient number of cases to yield statistically significant evaluation. The Cooperative Study Group of Surgical Adjuvant Chemotherapy for Gastric Cancer in Japan including 297 hospitals initiated its operation in 1975. The first study with cases revealed that the protocol consisting bolus intravenous injection of MMC plus oral administration of Futraful for 3 months was effective in improving 5-year survival of gastric cancer patients with stages III and IV and, for those with a positive metastasis into the lymph nodes, with obvious serosal invasion (n(+)ps. (+). This cooperative study group has been expanded in a form of The Japanese Foundation of Multi-disciplinary Treatment of Cancer in 1980. The study on efficacy of adjuvant immunochemotherapy for gastric cancer is on-going.
手术与化疗相结合对于提高胃癌患者的生存率至关重要。辅助化疗研究必须在对照试验的背景下进行，并且纳入足够数量的病例以得出具有统计学意义的评估结果。日本胃癌手术辅助化疗合作研究组由297家医院组成，于1975年开始运作。首例病例研究表明，采用大剂量静脉注射丝裂霉素（MMC）加口服喃氟啶（Futraful）持续3个月的方案，对于改善Ⅲ期和Ⅳ期胃癌患者以及那些伴有淋巴结转移阳性、明显浆膜侵犯（n(+)ps.(+)）患者的5年生存率是有效的。该合作研究组于1980年以日本癌症多学科治疗基金会的形式得以扩展。胃癌辅助免疫化疗的疗效研究正在进行中。
